Switch to:
Also traded in: Austria, Germany, Israel, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
MYL's Cash-to-Debt is ranked lower than
98% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. MYL: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
MYL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 2.99 Max: 49.83
Current: 0.03
0.02
49.83
Equity-to-Asset 0.36
MYL's Equity-to-Asset is ranked lower than
82% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MYL: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
MYL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.8 Max: 0.94
Current: 0.36
0.19
0.94
Debt-to-Equity 1.20
MYL's Debt-to-Equity is ranked lower than
88% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. MYL: 1.20 )
Ranked among companies with meaningful Debt-to-Equity only.
MYL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.05 Max: 2.73
Current: 1.2
0.01
2.73
Debt-to-EBITDA 4.64
MYL's Debt-to-EBITDA is ranked lower than
78% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. MYL: 4.64 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MYL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.19  Med: 4.72 Max: 7.37
Current: 4.64
3.19
7.37
Interest Coverage 1.97
MYL's Interest Coverage is ranked lower than
91% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. MYL: 1.97 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 1.96  Med: 3.08 Max: 4.02
Current: 1.97
1.96
4.02
Piotroski F-Score: 5
Altman Z-Score: 1.19
Beneish M-Score: -2.76
WACC vs ROIC
9.11%
3.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 9.09
MYL's Operating Margin % is ranked higher than
53% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. MYL: 9.09 )
Ranked among companies with meaningful Operating Margin % only.
MYL' s Operating Margin % Range Over the Past 10 Years
Min: 9.09  Med: 15.14 Max: 17.19
Current: 9.09
9.09
17.19
Net Margin % 4.71
MYL's Net Margin % is ranked lower than
56% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. MYL: 4.71 )
Ranked among companies with meaningful Net Margin % only.
MYL' s Net Margin % Range Over the Past 10 Years
Min: -3.53  Med: 7.55 Max: 12.04
Current: 4.71
-3.53
12.04
ROE % 4.26
MYL's ROE % is ranked lower than
57% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. MYL: 4.26 )
Ranked among companies with meaningful ROE % only.
MYL' s ROE % Range Over the Past 10 Years
Min: -14.72  Med: 9.83 Max: 29.99
Current: 4.26
-14.72
29.99
ROA % 1.57
MYL's ROA % is ranked lower than
58% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. MYL: 1.57 )
Ranked among companies with meaningful ROA % only.
MYL' s ROA % Range Over the Past 10 Years
Min: -2.47  Med: 3.77 Max: 5.97
Current: 1.57
-2.47
5.97
ROC (Joel Greenblatt) % 25.70
MYL's ROC (Joel Greenblatt) % is ranked higher than
68% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. MYL: 25.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MYL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 15.13  Med: 28.81 Max: 38.2
Current: 25.7
15.13
38.2
3-Year Revenue Growth Rate 4.60
MYL's 3-Year Revenue Growth Rate is ranked lower than
54% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MYL: 4.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MYL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.1  Med: 15.2 Max: 54.5
Current: 4.6
-6.1
54.5
3-Year EBITDA Growth Rate 8.70
MYL's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. MYL: 8.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MYL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.8  Med: 11.2 Max: 74.7
Current: 8.7
-18.8
74.7
3-Year EPS without NRI Growth Rate -17.80
MYL's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. MYL: -17.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MYL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.8 Max: 110.4
Current: -17.8
0
110.4
GuruFocus has detected 4 Warning Signs with Mylan NV MYL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MYL's 30-Y Financials

Financials (Next Earnings Date: 2019-03-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

MYL Guru Trades in Q4 2017

Tom Russo 2,540 sh (New)
Leon Cooperman 237,000 sh (New)
Francisco García Paramés 223,489 sh (New)
Joel Greenblatt 311,184 sh (+390.08%)
Steven Cohen 4,016,928 sh (+167.90%)
First Pacific Advisors 9,509,860 sh (+0.43%)
Diamond Hill Capital 17,383 sh (+8.78%)
Pioneer Investments 399,037 sh (+1039.65%)
Vanguard Health Care Fund 29,844,042 sh (unchged)
Steven Romick 7,425,690 sh (unchged)
Paul Tudor Jones Sold Out
David Einhorn 10,182,307 sh (-5.23%)
Richard Pzena 21,978,042 sh (-3.27%)
John Paulson 12,429,000 sh (-15.56%)
Mario Gabelli 6,500 sh (-55.17%)
» More
Q1 2018

MYL Guru Trades in Q1 2018

Paul Tudor Jones 31,216 sh (New)
Jim Simons 1,422,400 sh (New)
Pioneer Investments 420,346 sh (+5.34%)
Francisco García Paramés 283,793 sh (+26.98%)
Vanguard Health Care Fund 29,844,042 sh (unchged)
Steven Romick 7,425,690 sh (unchged)
Mario Gabelli 6,500 sh (unchged)
Joel Greenblatt Sold Out
Tom Russo Sold Out
Leon Cooperman Sold Out
David Einhorn 7,652,000 sh (-24.85%)
Richard Pzena 21,293,375 sh (-3.12%)
John Paulson 11,543,000 sh (-7.13%)
Steven Cohen 1,611,776 sh (-59.88%)
First Pacific Advisors 9,446,830 sh (-0.66%)
Diamond Hill Capital 7,780 sh (-55.24%)
» More
Q2 2018

MYL Guru Trades in Q2 2018

Vanguard Health Care Fund 30,606,342 sh (+2.55%)
Francisco García Paramés 367,018 sh (+29.33%)
Jim Simons 1,541,013 sh (+8.34%)
John Paulson 11,543,000 sh (unchged)
Steven Romick 7,425,690 sh (unchged)
Mario Gabelli 6,500 sh (unchged)
Paul Tudor Jones Sold Out
Diamond Hill Capital Sold Out
David Einhorn 6,859,000 sh (-10.36%)
Richard Pzena 21,115,152 sh (-0.84%)
Steven Cohen 1,001,200 sh (-37.88%)
First Pacific Advisors 9,369,310 sh (-0.82%)
Pioneer Investments 244,354 sh (-41.87%)
» More
Q3 2018

MYL Guru Trades in Q3 2018

Andreas Halvorsen 3,755,930 sh (New)
Caxton Associates 6,759 sh (New)
Vanguard Health Care Fund 31,108,842 sh (+1.64%)
Richard Pzena 21,657,877 sh (+2.57%)
Pioneer Investments 286,703 sh (+17.33%)
Steven Romick 7,425,690 sh (unchged)
Jim Simons Sold Out
David Einhorn Sold Out
Mario Gabelli 5,700 sh (-12.31%)
Francisco García Paramés 300,013 sh (-18.26%)
First Pacific Advisors 9,336,870 sh (-0.35%)
John Paulson 11,505,400 sh (-0.33%)
Steven Cohen 857,100 sh (-14.39%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}